Achieved Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth ...

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven ...

A 55-year-old man developed painful swelling that doctors later thought was arthritis. Subtle clues revealed something more ...

Johnson & Johnson , a worldwide leader in multiple myeloma therapies, today announced that the U.S. Food and Drug ...

If the rest of 2026 continues in this vein, we may look back on January and February as the moment the sector recognised that ...

Scientists are trying a revolutionary new approach to treat rheumatoid arthritis, multiple sclerosis, lupus, and other devastating autoimmune diseases – by reprogramming patients’ out-of-whack immune ...

A rare clotting disorder puzzled doctors during the COVID vaccine rollout. New research reveals the unlikely chain of events ...

Epcoritamab plus R-DHAX/C achieved 79% ORR and 69% CR, with median 1.4 months to response and early activity evident by the first week-6 assessment. Over half of patients reached ASCT after ...

Last summer, the Trump administration announced a voluntary pledge by health insurers to reform prior authorization, but patient advocates and medical providers remain skeptical.

A “living drug” was developed as a cancer treatment. Now it is showing promise for conditions, such as lupus and multiple sclerosis, that have long been considered incurable.

An antibody test for the infectious disease Mpox was successfully developed during the new clade 1b outbreak in Rwanda, the first time that an assay of its kind has been validated within this setting.

Over three quarters of people on Gazyva plus standard therapy achieved at least a four-point improvement in SRI-4, a measure that assesses disease severity and symptomsGazyva has the potential to ...